ClinicalTrials.gg
WithdrawnNCT03785184Updated Aug 28, 2019

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

A Phase 2 interventional study of venetoclax and lenalidomide in Multiple Myeloma, sponsored by AbbVie. Withdrawn at 22 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-28.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Strategic considerations

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing venetoclax in Multiple Myeloma — 4 open to participants now, 9 under way, 2 of them phase 3. venetoclax · Multiple Myeloma.

Enrollment
18th of 20
0 · median 42
Started
2019
with 4 others
Phase 2
6 of 20
2 open now
Registered
13th of 20
by date
Lead sponsor
10 of 20
AbbVie

Among the 20 studies testing venetoclax in Multiple Myeloma, this one is the 18th largest by enrollment, is one of 5 that started in 2019, is one of 6 in phase 2, and was the 13th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

4 of the 20 studies testing venetoclax in Multiple Myeloma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing venetoclax in Multiple Myeloma, or all of them as a file.
02

Study summary

This study will evaluate the safety and preliminary efficacy of venetoclax when combined with lenalidomide and dexamethasone for participants with newly diagnosed, active t(11;14) positive multiple myeloma (MM).

This study will consist of 2 parts: Part 1 Dose Escalation and Part 2 Dose Expansion.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Multiple Myeloma
  • Cancer
  • t(11;14)-Positive Multiple Myeloma
  • Venetoclax
  • Lenalidomide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have documented, confirmed active multiple myeloma (MM) with greater than or equal to 10% clonal bone marrow plasma cells or -proven bone or extramedullary plasmacytoma and any one or more of the following myeloma-defining events:

    • Evidence of end organ damage attributed to the underlying plasma cell proliferative disorder and satisfying at least one of the protocol specified laboratory criteria for calcium elevation, renal failure, anemia, or lytic bone lesions; OR
    • One or more of the biomarkers of as described in the protocol.
  • Must have MM positive for the t(11;14) translocation, as determined by methods described in the protocol.
  • Must have defined by at least one of the following criteria:

    • Serum M-protein ≥ 1.0 g/dL (immunoglobulin [Ig]G myeloma) or greater than or equal to 0.5 g/dL (IgA, IgM, IgD, or IgE myeloma);
    • Urine M-protein greater than or equal to 200 mg/24 hours;
    • Serum free light chain (FLC) greater than or equal to 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal.
  • Newly diagnosed and not considered a candidate for high-dose therapy and hematopoietic stem cell transplantation ()
  • Must have performance status less than or equal to 2.

Exclusion criteria

Exclusion Criteria:

  • Has a co-existing condition as specified in the protocol.
  • Has history of other active , including myelodysplastic syndromes (MDS) within the past 3 years with specific exceptions detailed in the protocol.
  • Has been treated with or received any of the following:

    • Prior or current systemic therapy or hematopoietic stem cell transplantation () for MM (a short course of treatment with equivalent to dexamethasone 40 mg/day for a maximum of 4 days is allowed before treatment); use of systemic strong or moderate inhibitor or inducer of cytochrome P450(CYP)3A within 7 days before the first dose of study drug.
    • Radiation therapy within 2 weeks of dosing
    • Plasmapheresis within 4 weeks of dosing
    • Immunization with within 8 weeks of dosing
  • Has a or inability to comply with antithrombotic prophylaxis.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Venetoclax + Lenalidomide + Dexamethasone

    Venetoclax up to 800 mg orally every day (QD) QD on Days 1 - 28 plus lenalidomide up to 25 mg orally QD on Days 1 - 21 (28 day cycle) plus dexamethasone up to 40 mg orally once weekly (QW).

    Drug: venetoclax · Drug: lenalidomide · Drug: dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participates Who Achieve CR

    Complete response (CR) is defined as negative immunofixation of serum and urine, and disappearance of any soft tissue plasmacytomas, and \< 5% plasma cells in bone marrow.

    Time frame: From baseline up to approximately 24 months

Secondary outcomes

  1. Percent of Participants Who Achieve MRD Negativity

    Minimal residual disease (MRD) negative after treatment is described as less than one myeloma cell per 100,000 bone marrow cells.

    Time frame: From baseline up to approximately 24 months

  2. Percent of Participants Who Achieve VGPR or Better

    Very Good Partial Response (VGPR) per international myeloma working group (IMWG) criteria is defined as serum or urine myeloma protein (m-protein) detectable by immunofixation but not on electrophoresis, or greater than or equal to 90% reduction in serum m-protein and urine m-protein less than 100 mg/24 hours.

    Time frame: From baseline up to approximately 24 months

  3. Overall Response Rate (ORR)

    ORR is described as the percentage of participants who experience partial response (PR) or better; PR per IMWG is described as follows: * ≥ 50% reduction of serum M-protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg/24 h * If the serum and urine M-protein are not measurable, a decrease ≥ 50% in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria * If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, ≥ 50% reduction in bone marrow plasma cells is required in place of M-protein, provided baseline percentage was ≥ 30% * In addition, if present at baseline, ≥ 50% reduction in size of soft tissue plasmacytomas is also required

    Time frame: From baseline up to approximately 24 months

  4. Time to Response (TTR)

    Time to response is defined as the time from randomization to the first response (CR, stringent complete response \[sCR\], VGPR, PR).

    Time frame: From baseline up to approximately 24 months

  5. Duration of response (DOR)

    DOR is defined as the time from first observation of PR to the time of disease progression, with deaths from causes other than progression censored.

    Time frame: Approximately 7 years

  6. Progression-free Survival (PFS)

    PFS is defined as time from start of the treatment to disease progression or death (regardless of cause of death), whichever comes first.

    Time frame: Approximately 7 years

  7. Minimal Residual Disease (MRD) Negativity Rate at 12 Months

    Percent of participants meeting the MRD Negative criteria at 12 months after initial dose; MRD Negative defined as less than one myeloma cell per 100,000 bone marrow cells.

    Time frame: Approximately 12 months after initial dose of study drug

  8. Time to Disease Progression (TTP)

    TTP is defined as the time from start of treatment to disease progression, with deaths from causes other than progression censored.

    Time frame: Approximately 7 years

  9. Time to Next Treatment (TTNT)

    The time to next treatment is defined as the time between the date of the first study drug intake and the date of the first next treatment intake after study drug discontinuation.

    Time frame: Approximately 7 years

  10. Overall Survival (OS) Rate

    OS was defined as the time from the date the participant was randomized to the date of death.

    Time frame: Approximately 7 years

07

Study locations

22 sites
  • City of Hope /ID# 212211
    Duarte, California 91010, United States
  • Marin Cancer Care /ID# 208476
    Greenbrae, California 94904, United States
  • University of California, Los Angeles /ID# 208516
    Los Angeles, California 90095, United States
  • Karmanos Cancer Institute /ID# 208805
    Detroit, Michigan 48201, United States
  • Henry Ford Hospital /ID# 208481
    Detroit, Michigan 48202, United States
  • Duke University Hospital /ID# 208306
    Durham, North Carolina 27710, United States
  • UPMC Hillman Cancer Ctr /ID# 208121
    Pittsburgh, Pennsylvania 15232, United States
  • Westmead Hospital /ID# 210267
    Westmead, New South Wales 2145, Australia
  • Flinders Centre for Innovation /ID# 210697
    Bedford Park, South Australia 5042, Australia
  • St. Vincents Hosp Melbourne /ID# 210266
    Fitzroy, Victoria 3065, Australia
  • Austin Hospital /ID# 210268
    Heidelberg, Victoria 3084, Australia
  • Monash Medical Centre /ID# 210269
    Melbourne, Victoria 3168, Australia
  • Tom Baker Cancer Centre /ID# 208549
    Calgary, Alberta T2N 4N2, Canada
  • Princess Margaret Cancer Centr /ID# 208923
    Toronto, Ontario M5G 2M9, Canada
  • Hopital Maisonneuver-Rosemont /ID# 208550
    Montreal, Quebec H1T 2M4, Canada
  • McGill Univ HC /ID# 208486
    Montreal, Quebec H3G 1A4, Canada
  • Clinica Universitar de Navarra - Pamplona /ID# 209883
    Pamplona, Navarra, Comunidad 31008, Spain
  • Hospital Clinic de Barcelona /ID# 209888
    Barcelona, 08036, Spain
  • Hspital Universitario Gregorio Maranon /ID# 209926
    Madrid, 28009, Spain
  • Clinica Universitar de Navarra - Madrid /ID# 210131
    Madrid, 28021, Spain
  • Hosp Univ 12 de Octubre /ID# 209887
    Madrid, 28041, Spain
  • Hospital Univ Dr. Peset /ID# 209884
    Valencia, 46017, Spain
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2018
First posted
Dec 24, 2018
StartEst.
Apr 29, 2019
Primary completionActual
Aug 22, 2019
CompletionActual
Aug 22, 2019
Last update
Aug 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03785184
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 24, 2018
Start date
Apr 29, 2019 (estimated)
Primary completion
Aug 22, 2019
Completion
Aug 22, 2019
Last update
Aug 28, 2019

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Lenalidomide · Dexamethasone

Start the discussion